GPC Shifts Satraplatin Focus From First-Line To Second; Study Cleared In SPA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The German biotech firm GPC will proceed with a Phase III trial of its oral prostate cancer therapy satraplatin as a second-line treatment following FDA’s clearance of a special protocol assessment.